Medicamentos genéricos no Brasil: impactos das políticas públicas sobre a indústria nacional

Abstract

Abstract

<b>Aquisição de medicamentos genéricos em município de médio porte</b>

“…The Generic Medications Policy should overcome two key limitations of the health industrial complex: the local entrepreneurial base for innovation and dedication to the health conditions of the Brazilian population. 12 Medicines with increased per unit cost The difference between the unit price of medicines procured in 2007 and 2008 is signifi cant. Even though 44 items had decreased costs, the overall impact of requiring the bioavailability and/or bioequivalence tests in procurement was an increase of more than two million reais in 2008 for the municipality.…”

“…Quality is assured by monitoring production facilities as well as through GMP, in accordance with RDC No. 210/ANVISA 12 ANVISA requires evidence of therapeutic equivalence of all oral medication prescribed by doctors, through demonstration of bioequivalence through relative bioavailability tests in vivo. For non-oral medications and non-prescription oral medications, therapeutic equivalence is proven by in vitro test for pharmaceutical equivalence.…”

Patentes farmacêuticas e saúde pública: desafios à política brasileira de acesso ao tratamento anti-retroviral

“…Primeiramente, coloca em dúvida a capacidade da indústria farmacêutica local de realizar a síntese de matéria-prima 7,37,53 . Em segundo lugar, o constante recurso a importações tende a desmobilizar a indústria local e acirrar a dependência de princípios ativos provenientes de fontes externas 64 .…”

“…Além do emprego de recursos públicos diretos em P&D, uma das medidas auxiliares ao objetivo de capacitação tecnológica trata da revisão da política de compras governamentais de insumos farmacêuticos, de modo a incentivar a participação do setor privado 64 . O apoio à produção de medicamentos genéricos de qualidade tratase de uma medida importante para manter ativa a produção interna.…”

Windows of opportunities and technological innovation in the Brazilian pharmaceutical industry

“…Is access to knowledge derived from expired patents contributing to process improvements and an increase in the production scale, making internal research and development (R&D) activities feasible for these companies? National companies sustain that hypothesis, but some authors argue that production of generics will generate an environment of accommodation, harmful to technological innovation 5 .…”